Currently, four monoclonal antibodies (mAb) targeting the extracellular domain of EGFR are approved for clinical use against various cancers of epithelial origin (e.g., colorectal cancer (CRC) and head and neck cancer) [20]. This evidence concerns the gene EGFR and colorectal cancer.